---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-003471"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T16:00:11.209401+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# VYNE shareholders approve reverse stock split; receives $5M deferred payment; redeems preferred

## Summary
- Stockholders approved reverse stock split at ratio from 1:10 to 1:25; board to set effective date within one year.
- Series A Preferred redeemed for $360,000 on Jan 17, 2023; Certificate of Elimination to be filed.
- Received $5.0M deferred payment from Journey Medical per Asset Purchase Agreement; pro forma cash $35.9M as of Dec 31, 2022.

## SEC filing metadata
- accession: 0001104659-23-003471
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 5.07, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/0001104659-23-003471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/tm233167d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-003471
- JSON: https://secwatch.observer/filing/0001104659-23-003471.json
- Plain text: https://secwatch.observer/filing/0001104659-23-003471.txt

## Key facts
- Shareholder Votes
  VYNE Therapeutics Inc. shareholders approved Adjournment Proposal at the 2023-01-12 meeting.
  - Outcome: passed
  - Meeting: 2023-01-12
  source text: With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,029,283; votes “Against” were 3,693,414; votes abstaining or withheld were 423,246, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,624,348,039 403,374,658 423,246 The Adjournment Proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/0001104659-23-003471-index.htm
- Shareholder Votes
  VYNE Therapeutics Inc. shareholders approved Reverse Stock Split Proposal at the 2023-01-12 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-01-12
  source text: With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,230,441; votes “Against” were 3,711,239; votes abstaining or withheld were 204,263, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,625,767,750 402,173,930 204,263 The Reverse Stock Split Proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/0001104659-23-003471-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.